reporting req for meds
TRANSCRIPT
-
7/27/2019 Reporting Req for Meds
1/19
GUIDANCE FOR INDUSTRY
SAFETY REPORTING REQUIREMENTS FOR
REGISTERED MEDICINAL PRODUCTS
APRIL 2011
-
7/27/2019 Reporting Req for Meds
2/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
2
TABLE OF CONTENTS
1 Introduction . 3
1.1 Purpose & scope ... 3
1.2 Background 3
2 Responsibilities of product licence holder.. 3
3 Reporting requirements ... 4
3.1 Spontaneous suspected AR reports .. 4
3.1.1 Fatal or Life-threatening Spontaneous Suspected AR reports 43.1.2 All other serious spontaneous suspected AR reports ... 53.1.3 Contents of suspected AR reports .... 5
3.1.4 Follow-up reports ..... 53.1.5 AR reporting forms ... 53.1.6 Local non-serious AR reports & overseas AR reports ... 63.1.7 Reports from consumers . 6
3.2 Scientific literature & other post-marketing safety information ... 6
4 Reporting requirements in special situations 6
4.1 The period between submission for registration & the granting of a productlicence . 6
4.2 Unregistered medicinal products ........ 74.3 Lack of efficacy .. 74.4 Reporting of outcomes of use during pregnancy . 7
4.5 Drug overdoses . 7
5 Periodic safety update report (PSUR) .. 8
5.1 Reporting requirements .... 85.2 Content of PSUR ... 8
6 Update of regulatory authority or company actions taken for safety reasons. 9
Annex I Summary of safety reporting requirements .... 10
Annex II (a) AR and Vaccine Adverse Event reporting forms ... 11
Annex II (b) General instructions for filling up the AR reporting form ...... 15
Annex III Periodic safety update report submission form . 16
Annex IV Glossary ... 17
-
7/27/2019 Reporting Req for Meds
3/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
3
1 INTRODUCTION
1.1 PURPOSE & SCOPE
The purpose of this document is to guide product licence holder on the submission of
relevant safety information to the Vigilance Branch of the Health Products Regulation Group
(HPRG) of the Health Sciences Authority (HSA).
This guidance applies to product licence holder who is responsible for introducing registered
medicinal products into Singapore. It addresses the types of documents to be submitted, the
timelines and the requirements for reporting safety information of medicinal products. The
topics covered include the following:
Spontaneous suspected adverse reaction (AR) reports
AR reporting in special situations Periodic safety update reports (PSURs)
Update of regulatory authority or company actions taken for safety reasons
1.2 BACKGROUND
When a new medicinal product is submitted for registration, the demonstration of its efficacy
and the evaluation of its safety are generally based on a small number of patients. The
limited number of patients included in clinical trials, the exclusion of certain patient groups at
risk, the lack of significant long-term treatment experience, and limitation of concomitant
therapies do not allow a thorough evaluation of the safety profile. Under such circumstances,
the detection or confirmation of rare ARs is particularly difficult during the pre-registration
development of the product.
In order to develop a comprehensive picture of clinical safety, marketed medicinal products
have to be closely monitored for their safety when used in actual practice. Surveillance of
registered medicinal products is a shared responsibility between the regulatory authority and
the product licence holder.
2 RESPONSIBILITIES OF PRODUCT LICENCE HOLDER
The product licence holder must have a system in-place that will assure the responsibility and
liability for its products on the market and to be able to take appropriate action, when
necessary. Written procedures for the receipt, evaluation and reporting of ARs should be
established.
-
7/27/2019 Reporting Req for Meds
4/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
4
The product licence holder should also appoint a person responsible for matters relating to
product safety. It is the responsibility of the product licence holder to contact the Vigilance
(VB) Branch, HPRG, proactively whenever there are any changes in the contact details, such
as the name of person responsible, designation, telephone number, fax number, email
address and mailing address. The contact details should be maintained up-to-date at all
times.
The responsibilities of the designated person are:
To report all safety information as described in this guidance to the HPRG.
To respond promptly to any request for provision of information necessary for the
evaluation of the benefits and risks of a medicinal product. This includes the
sales figures and the list of purchasers.
3 REPORTING REQUIREMENTS
The product licence holder is responsible for reporting suspected ARs to the HPRG and
should keep a record of, or have access to, all reports of suspected ARs that are received
from all sources including healthcare professionals, published / unpublished studies and
reports.
3.1 SPONTANEOUS SUSPECTED AR REPORTS
A spontaneous report is a clinical observation that originates outside of a formal study. An AR
is suspected if either the reporting person or the product licence holder believes there is a
possible causal relationship between the adverse reactions and medicinal products in
question. Spontaneous reports of suspected ARs should be reported to the Vigilance Branch,
HPRG, even if the product licence holderdoes not agree with the reporters assessment of a
possible causal association, or if the reporter has not provided a causal assessment. Adverse
events which are not suspected of being product-related by the healthcare professional
attending to the patient should not be reported unless the product licence holder has reasons
to suspect a causal association.
3.1.1 FATAL OR LIFE-THREATENING SPONTANEOUS SUSPECTED AR REPORTS
All fatal or life-threatening spontaneous ARs occurring in Singapore should be reported to the
Vigilance Branch, HPRG as soon as possible but no later than 7 calendar days after first
knowledge by the product licence holder, followed by as complete a report as possible within
8 additional calendar days.
http://www.hsa.gov.sg/docs/contactinfor.dochttp://www.hsa.gov.sg/docs/contactinfor.doc -
7/27/2019 Reporting Req for Meds
5/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
5
3.1.2 ALL OTHER SERIOUSSPONTANEOUS SUSPECTED AR REPORTS
All other serious spontaneous ARs occurring in Singapore should be reported to the Vigilance
Branch, HPRG as soon as possible and no later than 15 calendar days after first knowledge
by the product licence holder. The clock for reporting starts as soon as any personnel of the
product licence holder, including sales representatives, is made aware of the ARs.
3.1.3 CONTENTS OF SUSPECTED AR REPORTS
The AR reports should be as complete as possible and contain essential information to
facilitate assessment.
The minimum information required for the submission of an initial AR report are:
An identifiable patient,
An identifiable reporting source,
One or more adverse reaction(s), and
One or more suspected medicinal product(s).
The product licence holder should include the name, profession and place of practice of the
person making the report to facilitate the detection of duplicate reports.
The product licence holder may comment on whether there is a causal association between
the suspected product(s) and adverse reaction(s) and should provide the explanation on
which the causality assessment is made.
3.1.4 FOLLOW-UP REPORTS
To assist in the evaluation of the AR reports, additional information not available at the time
of the initial report should be provided in the form of follow-up reports within 15 calendar days
of receipt of new information. The reports should be clearly labelled as follow-up reports (with
appropriate cross-referencing).
3.1.5 AR REPORTING FORMS
The product licence holder can submit the AR report to the Vigilance Branch (VB), HPRG,
using the reporting form prescribed by the unit (see Annex II) or the CIOMS I form. The AR
reporting form can be downloaded fromhttp://www.hsa.gov.sg/adr_form. The completed AR
reports can be sent via mail, fax or email to the VB. Online AR reporting is also
available athttp://www.hsa.gov.sg/ae_online
http://www.hsa.gov.sg/adr_formhttp://www.hsa.gov.sg/adr_formhttp://www.hsa.gov.sg/adr_formhttp://www.hsa.gov.sg/ae_onlinehttp://www.hsa.gov.sg/ae_onlinehttp://www.hsa.gov.sg/ae_onlinehttp://www.hsa.gov.sg/ae_onlinehttp://www.hsa.gov.sg/adr_form -
7/27/2019 Reporting Req for Meds
6/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
6
3.1.6 LOCAL NON-SERIOUS AR REPORTS & OVERSEAS AR REPORTS
Local spontaneous reports of non-serious ARs and AR reports occurring outside of
Singapore need not be reported to the HPRG on a regular basis, but should be made
available upon request or prepared as line-listings in a Periodic Safety Update Report (if one
is required, see section 5).
3.1.7 REPORTS FROM CONSUMERS
Consumers should be encouraged to seek medical attention and get the attending healthcare
professional to report the AR. This is in recognition of the difficulties posed by the lack of
medical details and clinical information for consumer reports. When a consumer is unwilling
or unable to do this, the product licence holder should attempt to obtain as much information
from the consumer. If the adverse reaction is serious, the product licence holder should
obtain from the consumer voluntary informed consent to contact the treating healthcare
provider or relevant information e.g. medical documentation. When there is a reason to
suspect a causal association, a report must be submitted to the Vigilance Branch (indicating
on the reporting form that it is a consumer report).
3.2 SCIENTIFIC LITERATURE & OTHER POSTMARKETING SAFETY INFORMATION
As soon as the product licence holder is aware of any scientific / medical literature or
information from unpublished / published study reports, surveys, registries that could change
the risk-benefit balance of the registered product, this should be communicated to the
Vigilance Branch within 15 calendar days after first knowledge by the product licence holder.
A copy of the relevant report should be provided. If the report is not in English, submission of
a summary or translation in English is required.
4 REPORTING REQUIREMENTS IN SPECIAL SITUATIONS
There are some situations that are not covered directly by the reporting requirements detailed
in section 3.
4.1 THE PERIOD BETWEEN SUBMISSION FOR REGISTRATION & THE GRANTING OF A
PRODUCT LICENCE
In the period between submission for registration and the granting of a product licence, it is
the responsibility of the applicant to ensure that any new safety information which may impact
the benefit to risk balance of the product is immediately submitted to the Pharmaceuticals &
Biologics Branch (PBB), Pre-marketing Division , HPRG.
-
7/27/2019 Reporting Req for Meds
7/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
7
What constitutes a change to the benefit to risk balance is a matter of judgement for the
applicant but an applicant may be required to justify a decision not to report to HSA. For
example, another report of a well-known adverse reaction would not be significant, but a
report of an unexpected or new serious suspected reaction with good evidence of a causal
relationship, or where there is suspicion of a change in the frequency or severity of a known
effect, would be considered relevant to the evaluation. Similarly, results from studies which
impact on the assessment of efficacy would be significant. The applicant is required to submit
a tabulation
of serious unexpected ARs that are not mentioned in the proposed Singapore package insert
and have not been submitted previously.
4.2 UNREGISTERED MEDICINAL PRODUCTS
The product licence holder importing medicinal products which are not registered with the
HPRG, other than those for use in clinical trials, should report all suspected cases of local
serious ARs to the Vigilance Branch if the information is made available to them. The product
licence holder should follow the requirements for AR reporting as set out in section 3 and
indicate that the suspected product reported is exempted from registration.
4.3 LACK OF EFFICACY
Local reports of lack of efficacy should be reported to the Vigilance Branch within 15 calendar
days after first knowledge by the product licence holder. The underlying principle is that if amedicinal product fails to produce the expected pharmacological or therapeutic benefit, there
may be an adverse outcome for the patient, including a worsening of the condition for which
the medication is being taken.
4.4 REPORTING OF OUTCOMES OF USE DURING PREGNANCY
In the event that a product licence holder is aware that its product which is not recommended
for use during pregnancy has been consumed by a pregnant patient, the product licence
holder should follow-up with the doctor on the pregnancy outcome. If a pregnancy results in a
serious or an abnormal outcome which the reporting doctor considers might be due to the
product, the product licence holder must submit the AR report to the Vigilance Branch within
15 calendar days after first knowledge by the product licence holder.
4.5 DRUG OVERDOSES
The product licence holder need not report cases of drug overdoses.
-
7/27/2019 Reporting Req for Meds
8/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
8
5 PERIODIC SAFETY UPDATE REPORT (PSUR)
5.1 REPORTING REQUIREMENTS
PSURs may be requested for selected registered medicinal products. If requested, PSURs
are required to be submitted to the Vigilance Branch, Vigilance, Compliance and
Enforcement Division, HPRG, 6-monthly for the first 2 years after marketing approval, after
which they are to be submitted on a yearly basis for the subsequent 3 years. This timeframe
may be varied in order to harmonise periodic safety updates internationally.
Data lock points may be set according to the international birthdate of the medicinal product.
Each PSUR should cover the period of time since the last update report and should be
submitted within 60 days of the data lock point. Where there are reasons to continue the
safety monitoring of a particular product, the HPRG may request for PSURs to be submitted
after the initial 5 years of marketing approval.
For other registered products, PSURs are not required to be submitted on a regular basis.
However, PSURs or a summary report of safety data should be maintained for the first 5
years of marketing approval and made available to the HPRG upon request. In the event of a
major safety concern, the HPRG may request for PSURs or a summary report of safety data
to be submitted within a shorter timeframe.
Each PSUR submitted should be accompanied with the following:
A copy of the most updated local package insert and patient information leaflet (if
any).
A PSUR submission form (see Annex III). The form includes an estimate of drug
usage and/or patient exposure (e.g. local sales figures, patient-years exposed,
number of prescriptions if available) in relation to the period covered in the
PSURs.
5.2 CONTENT OF PSUR
For guidance on the format and content of the PSURs, refer to the latest version of the
International Conference on Harmonisation (ICH) on the Guidance for Industry E2C Clinical
Safety Data Management: Periodic Safety Update Reports for Marketed Drugs. This can be
found athttp://www.ich.org.
http://www.ich.org/http://www.ich.org/http://www.ich.org/http://www.ich.org/ -
7/27/2019 Reporting Req for Meds
9/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
9
6 UPDATE OF REGULATORY AUTHORITY OR COMPANY ACTIONS TAKEN FOR
SAFETY REASONS
In the event of any regulatory actions taken by other regulatory authorities or action(s) taken
by the company i.e. product owner arising from significant safety issues, the product licence
holder must inform the Vigilance Branch promptly, as soon as the product licence holder is
made aware of these issues.
Significant safety issues are those which may influence the overall benefit and risk of the
product such as:
Product withdrawal / recall and product defects
(The reporting timeline for the above is 24 hours upon receipt of information by
the product licence holder. Refer to the Guidelines on Product Defect Reporting
and Recall Procedures issued by the Enforcement Branch (EB), HPRG.
Removal of approved indications by reference regulatory agencies*
Failure to obtain a product licence renewal due to safety reasons
Dissemination of Dear Healthcare Professional Letter related to safety issues
The Vigilance Branch should be notified no later than 7 calendar days from the first receipt of
information by the product licence holder.
The safety related reasons that led to these actions should be described and documentation
appended where appropriate. Each notification should be accompanied with an assessment
by the product licence holder, of the significance of the regulatory action in the local context
and recommendation(s) on follow-up action(s) to be undertaken locally. Any intention of
voluntary local withdrawal / discontinuation of a registered medicinal product by the product
licence holder arising from safety issues should be discussed with HPRG at an early stage.
For enquiries on this document, please refer to:Vigilance Branch, Health Products Regulation Group
Health Sciences Authority
11 Biopolis Way
#11-03, Helios
Singapore 138667
Tel: (65) 6866 3538; Fax: (65) 6478 9069
Email:[email protected]
* Reference regulatory agencies refer to US FDA, UK MHRA, Australia TGA, EU EMEA and Health Canada.
mailto:[email protected]:[email protected]:[email protected]:[email protected] -
7/27/2019 Reporting Req for Meds
10/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
10
ANNEX I
SUMMARY OF SAFETY REPORTING REQUIREMENTS
The summary of the reporting requirements is shown in the table below (for the detailedrequirements, please refer to the relevant sections of the guidance document):
Types of
information
Description Reporting timeframe Submit
to
Local reports(spontaneous)
Section 3
Fatal or life-threatening ARs No later than 7 calendardays after first knowledgeby the product licenceholder, followed by ascomplete a report aspossible within 8 additionalcalendar days.
VB
All other serious ARs No later than 15 calendardays after first knowledge
by the product licenceholder.
Non-serious ARs Not required on a routinebasis.
-
Foreign reports(spontaneous)
Section 3
Serious ARs Not required on a routinebasis.
-
Non-serious ARs Not required on a routinebasis.
-
Periodic safetyupdate reports(PSURs)
Section 5
For selected products only 6 monthly for first 2 yearsafter marketing approval,then annually forsubsequent 3 years orharmonised according tointernational requirements.
PBB
Update ofregulatoryauthority orcompany actionstaken for safetyreasons
Section 6
Product withdrawal / product recall /product defect
Within 24 hrs after firstknowledge by the productlicence holder.
EB
Significant safety issues such as:
Removal of approved indicationsby reference agencies
Failure to obtain a product licencerenewal due to safety reasons
Dissemination of Dear HealthcareProfessional Letter related tosafety issues
Within 7 calendar days
from initiation of actions bythe relevant authority or byproduct owner.
VB
EB: Enforcement BranchPBB: Pharmaceuticals & Biologics BranchVB: Vigilance Branch
-
7/27/2019 Reporting Req for Meds
11/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
11
ANNEX II (a)
HSA AR REPORTING FORM
Front
-
7/27/2019 Reporting Req for Meds
12/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
12
Back
-
7/27/2019 Reporting Req for Meds
13/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
13
Front
-
7/27/2019 Reporting Req for Meds
14/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
14
Back
-
7/27/2019 Reporting Req for Meds
15/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
15
ANNEX II (b)
GENERAL INSTRUCTIONS FOR FILLING UP THE AR REPORTING FORM
SECTION I - PARTICULARS OF PATIENT
The patients identifiers include initials, record number, age, weight, gender and ethnic group.This information should be as complete as possible as they are used to identify duplicate reports.
SECTION II - DETAILS OF ADVERSE REACTION (AR)
Date of onset of AR
If the date is not available, provide the best estimate of the date of first occurrence of AR.
Description of AR
Describe the nature of AR, its localisation, severity and characteristics.
Outcome attributed to the AR
Indicate the consequences of the AR for the patient (including the date of recovery or death ifavailable), using the worst of the different outcomes for multiple reactions.
Sequelae
Indicate the sequelae (any permanent complications or injuries as a result of the AR) if thisinformation is available.
SUSPECTED DRUG(S) / CONCOMITANT DRUG(S)
Suspected drug(s)
Provide either the brand name (preferred) or active ingredient(s) of the medicinal product, alsostate the dose, frequency, route, start date, end date and indication for which the drug was given(batch numbers are important for vaccines). If the exact dates are unknown, provide the bestestimate of date(s) of therapy.
Other concomitant drug(s)
Indicate whether the patient was on any other medication and provide a list of medicinal productsthat the patient has been given at the same time or 3 months before the onset of the AR.
Other relevant information
Provide any other relevant information that could help in the assessment of the temporalrelationship between the observed AR and suspected medicinal product(s). This includes pre-existing medical conditions, renal and hepatic functions, known allergies, pregnancy, smoking oralcohol use, reappearance of AR with same drug(s) upon rechallenge and relevant laboratoryresults. Attach additional pages if necessary.
SECTION III - MANAGEMENT OF REACTION
Indicate if the patient was hospitalised as a result of the AR and whether the AR was consideredserious. Indicate if any treatment was given for the management of the AR.
SECTION IV - PARTICULARS OF REPORTER
Indicate the companys name and contact number. Each report should also include the name,profession and practice address of the person making the AR report to the company. These areessential for verification and for further case follow-up if required.
Use NIL when no information is available. Additional information should be provided when availableat a later date. Please indicate that it is a follow-up report. Cross-referencing of follow-up reports isessential to facilitate the detection of duplicate reports.
-
7/27/2019 Reporting Req for Meds
16/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
16
ANNEX IIIHEALTH PRODUCTS REGULATION GROUP, HEALTH SCIENCES AUTHORITY
PERIODIC SAFETY UPDATE REPORT SUBMISSION FORM
I Product information
Brand name:
Active ingredient(s):
Local birthdate(Date of registration):
II PSUR information
International birthdate:
Period covered by thisreport (data lock point):
Total number of volume for
current submission:
III Sale figures (Singapore)
Please indicate the local sales volume and/or estimated patient exposure for the same periodcovered in the PSUR.
IV Company particulars
Company:
Address:
Name of personnel:
Designation of personnel:
Telephone number:
Fax number:
Email address:
Signature / date:
V Comments
http://www.hsa.gov.sg/docs/PSUR_submission_form.dochttp://www.hsa.gov.sg/docs/PSUR_submission_form.doc -
7/27/2019 Reporting Req for Meds
17/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
17
ANNEX IV
GLOSSARY
1. Adverse reaction (AR)
An adverse reaction to a health product means any adverse effect that is unintended and
occurs in association with the use or administration of the product at doses normally
used in man for the prophylaxis, diagnosis, or therapy of disease or for the restoration,
correction or modification of physiological function.
2. Causality assessment
Determination of whether there is reasonable possibility that the product is etiologically
related to the adverse reaction. Causality assessment includes assessment of temporal
relationships, dechallenge / rechallenge information, association with (or lack of
association with) underlying disease, presence (or absence) of a more likely cause,
plausibility.
3. CIOMS I form
An adverse reaction reporting form developed by the Council for International
Organisations of Medical Sciences (CIOMS), intended for notifying the regulatory
authorities of countries other than the country where the report originated.
4. Data Lock Point (cut-off date)
The date designated as the cut-off date for data to be included in a periodic safety
update report (PSUR).
5. International birthdate (IBD)
The date of the first marketing approval for a medicinal product granted to a licence
holder product licence holder in any country in the world.
6 Product licence holder
The company or legal entity responsible for introducing (one or more consignments of) a
western medicinal product into the Singapore market, and which has been granted
authorisation to do so by way of a product licence or import licence. This party is
responsible for each consignment of the product that it has introduced into the market,
and this responsibility extends to all aspects of the product including safety, quality and
continued compliance with the conditions attached to the licence. The party must subject
to the jurisdiction of the country that issued the authorisation, which normally means
being physically located in that country.
-
7/27/2019 Reporting Req for Meds
18/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
18
7 Periodic safety update report (PSUR)
An integrated summary assessment of all adverse reaction reports, both serious and
non-serious. It records information on medicinal product safety from different sources
and is collated to allow for mutual exchange of safety data among regulatory authorities.
8 Product owner
A company who is the legal / registered owner of the product formulation and / or the
manufacturing process pertaining to the product, and with whom the product licence
holder has a contract.
9 Serious adverse reaction (AR)
A serious adverse reaction to a health product means an adverse reaction that
results in a persons death.
threatens a persons life
results in a person being hospitalised as an in-patient or prolongs a
persons existing stay in hospital
results in a persons persistent or significant disability or incapacity.
results in a congenital anomaly or birth defect; or
is judged to be medically important even though the event might not be
immediately life-threatening or result in death or hospitalisation, but might
jeopardise the person or might require intervention to prevent one of the
other outcomes listed above.
NB: The term life-threatening in the definition of serious refers to an event in which the
patient was at risk of death at the time of event; it does not refer to an event which
hypothetically might have caused death if it were more severe.
Medical judgement should be exercised in deciding whether a reaction is serious in other
situations. Important adverse reactions that are not immediately life-threatening or do not
result in death or hospitalisation but may jeopardise the patient should be considered asserious.
10. Spontaneous adverse reaction (AR) reports
Also referred to as voluntary, unsolicited or anecdotal reports. It is a clinical observation
that originates outside of a formal study.
-
7/27/2019 Reporting Req for Meds
19/19
Guidance for Industry Safety Reporting Requirements for Registered Medicinal Products April 2011
Contact:
Vigilance BranchVigilance, Compliance & Enforcement Division
Health Products Regulation GroupHealth Sciences Authority
11 Biopolis Way, #11-03 HeliosSingapore 138667www.hsa.gov.sgTel: 6866 3538
Fax: 6478 9069